BRIDGES Study for Overactive Bladder
The BRIDGES Study is a multi-center research study comparing fesoterodine (Toviaz), an FDA approved medication, to placebo in women diagnosed with urgency urinary incontinence and overactive bladder by the 3 Incontinence Questions (3IQ). Approximately 636 women, at 13 clinical sites across the United States, will receive 12 weeks of fesoterodine or matching placebo. Women who complete the 12-week study will be offered open-label fesoterodine (Toviaz) for an additional 9 months.
If you are a healthy woman, age 18 or older, and experience urinary leakage daily, on average, you may qualify to participate in the BRIDGES Study. To see if you qualify for the study, please contact the clinical site in your area. The clinical sites currently recruiting for BRIDGES are:
|
City |
Institution |
Contact |
|
Providence, RI |
Brown Medical School/Women and Infant’s Hospital of RI |
401-274-1122 x2811 |
|
Birmingham, AL |
University of Alabama at Birmingham |
205-934-1777 |
|
Portland, OR |
Oregon Health and Science University |
(503) 494-3666 |
|
San Diego, CA |
University of California, San Diego |
858-822-5707 |
|
San Francisco, CA |
University of California, San Francisco |
415-885-7547 |
|
Iowa City, IA |
University of Iowa Carver College of Medicine |
319-384-8028 |
|
Ann Arbor, MI |
University of Michigan |
734-763-0666 |
|
Albuquerque, NM |
University of New Mexico, Health Sciences Center |
505-272-6311 |
|
Philadelphia, PA |
University of Pennsylvania |
215-615-4202 |
|
Pittsburgh, PA |
University of Pittsburgh |
412-586-9796 |
|
Memphis, TN |
University of Tennessee Health Science Center |
901 448-8400 |
|
San Antonio, TX |
University of Texas Health Science at San Antonio |
210-567-0550 or 210-567-1130 |
|
Charlottesville, VA |
University of Virginia |
434-243-4722 |
